The Need – Diagnosing LUTS

Lower Urinary Tract Symptoms (LUTS) – Obstruction, Voiding problem, Irritation, Incomplete emptying, Urgency, Incontinence

Urine testing is the most commonly used monitoring technique to analyse general health condition (Urinalysis) and Lower Urinary Tract Symptoms (Uroflowmetry) 

• Current testing – cumbersome, at hospitals, capital equipment

• Results are not immediate 

• No continuous monitoring and predictive insights

​

Our vision

To provide predictive and preventive medicine with digital health solutions allowing big data analysis based on urine testing offering

• Easy to use, at home testing, cost effective solutions

• Immediate results

• Continuous monitoring with predictive insights

​

Flometrica’s technology provides the opportunity for a comprehensive platform with products and services addressing both patients suffering from urological and renal symptoms, as well as the general public for continuous monitoring of their health condition. Our first product FloRite, is a disposable and affordable “smart cup” integrated with multiple sensors and Bluetooth connectivity, which measures the patient’s urine parameters and transmits them via the patient’s mobile device to a cloud database for big data and AI analysis. FloRite will be launched in Europe during 2020.

The company’s technology will be implemented in several applications: Digital Health solution for early diagnosis of LowerUrinaryTractSymptoms(LUTS)andurinalysistesting;bigdataanalysis(SaaS service)forchronicpatientsand physicians; digital solution for monitoring uroflowmetry secretion of hospitalised patients. 

​

FloRite™- Improving ease of use, enabling privacy  

Big data features to support diagnosis & treatment

​

FloRite - A “smart cup” for monitoring patient’s urinary tract functionality and general health condition at home or at the Point of Care (PoC), by recording Uroflowmetry and Urinalysis parameters. The results are transmitted via the patient’s mobile device to a cloud database for a big data analysis. FloRite will first solve the inefficiencies associated with diagnosing patients suffering from LUTS.The problem with existing methods of diagnosing LUTS was identified by several physicians. (See Ref.). FloRite will streamline and shorten the diagnosis process, provide accurate and immediate results and will ease the currently experienced burden of patients to a minimum. 

Flometrica will leverage its technology and offer additional products

​

DiaryRite - This is an add-on software application which combines the readings of FloRite during 3 or more consecutive days, together with records of the patient’s liquid intakes during the same period. DiaryRite will be launched in Europe immediately after launching FloRite. It is estimated that 50% of FloRite patients will need the DiaryRite application as well.

​

DataRite – Big data analysis service that will be implemented for revealing trend analysis and new knowledge-based recommendations.This service will provide insights regarding the efficacy of medication treatments, patient lifestyle and general health conditions and would be used as a tool of predictive and preventive medicine. Flometrica products are the channels and the tools to gather the information constituting this database. This cloud database will start functioning with the launch of FloRite and DiaryRite.To provide a comprehensive picture of the patient’s condition, Flometrica will develop a home based urinalysis device, performed by the patient at home, which will target chronic patients suffering from diabetes and hypertension, who are prone to suffer from kidney disease and need to continuously monitor their kidney health.

​

MeteRite – This is a disposable smart urinary drainage bags which will be used in hospitals, to monitor patient’s urine secretion, and provides alerts to the medical stuff when a decreased urine output is identified. Flometrica will utilise its approved IP to implement this solution providing an answer for the growing problem of Acute Kidney Injury (AKI), which is associated with hospitalised patients and specifically with ICU patients. (See Ref.)